Wholesale selling prices in Germany were 5.3% higher in July 2026 than a year earlier and 0.2% higher than in June 2026. For pharmacies, pharmaceutical wholesalers and logistics providers, this is not a medicine-price index. It is nevertheless an important cost signal: energy, metals, chemical products and IT affect delivery routes, cold chains, packaging, warehouses and technical systems.
July 2026: the figures at a glance
According to the official data from the Federal Statistical Office, the overall index rose by 5.3% year on year. The annual rate had been 4.9% in June and 5.9% in May. Compared with the previous month, the July index increased by 0.2%.
- Mineral oil products: up 24.1% year on year and 4.0% month on month.
- Non-ferrous ores, metals and semi-finished products: up 27.8% year on year but down 3.9% from June.
- Chemical products: up 13.1% year on year and down 1.1% month on month.
- Information and communication equipment: up 9.0% year on year and 1.1% month on month.
The month-on-month movements show why no single figure should be extrapolated mechanically. Procurement and logistics decisions should combine annual and monthly changes with the actual contract, volume and consumption profile.
The index is not a medicine-price index
The wholesale price index measures price developments for goods sold by wholesale companies. It does not mean that medicine or pharmacy retail prices rise at the same rate. In Germany, regulated components apply to prescription medicines under the Ordinance on the Pricing of Medicinal Products. Indirect operating costs can therefore rise without being passed through automatically in the medicine price.
The index still matters operationally. Pharmaceutical supply requires qualified storage, vehicles, fuel, refrigeration, packaging, sensors, IT, maintenance and trained staff. Those are the points where current price movements reach the pharmaceutical supply chain.
Energy affects routes, cold stores and the last mile
The sharp increase in mineral oil prices can directly affect route economics. Closely timed multi-drop deliveries, emergency runs, small drop sizes and long rural routes are particularly sensitive. Temperature-controlled distribution also needs energy for refrigeration, pre-conditioning, cross-docking and monitoring.
The EU Guidelines on Good Distribution Practice require storage and transport conditions to preserve medicine quality. Cost pressure cannot justify unqualified routes or reduced temperature control. Any economic optimisation has to remain within a demonstrably safe GDP process.
Five route metrics worth separating
- cost per stop, kilometre, shipment and delivered pack,
- share of express, emergency and repeat journeys,
- utilisation by time window, region and temperature band,
- energy used by cold storage, hubs and vehicle refrigeration,
- costs of deviations, returns and second delivery attempts.
A portfolio-wide average can hide expensive exceptions. A robust cost-to-serve model shows which service commitments protect supply and which process variants merely create avoidable cost.
Metals affect packaging and warehouse technology
Non-ferrous metals matter to pharma beyond commodity trading. Aluminium is used in blisters, foils and insulation, while copper and other metals are found in refrigeration, building services, conveyor technology, scanners and power systems. Price movements can therefore affect capital expenditure, maintenance, spare parts and packaging even when the purchase price of a medicine is unchanged.
Contracts should distinguish volatile market prices from costs that are actually relevant to the service. Index clauses need a defined reference, base period, adjustment interval, cap and evidence requirement. A generic index pass-through is often too broad for specialised pharmaceutical services.
Chemicals and IT add indirect operating costs
Chemical products may influence cleaning agents, disinfectants, process materials and parts of packaging. Higher ICT prices can affect scanners, mobile data capture, networks, temperature data loggers and warehouse IT. Each position may be smaller than medicine procurement, but together they support process capability and compliance.
Investment decisions should therefore use total cost of ownership: purchase, energy, maintenance, calibration, software, replacement cycles, downtime risk and training belong in one calculation.
Pharmacies: costs can rise without automatic price pass-through
Pharmacies experience the change through home delivery, energy, refrigeration, packaging, technology and supplier terms. For prescription medicines, Section 2 of the pricing ordinance and Section 3 for pharmacies set the legal framework. Additional operating costs cannot simply be added to a freely calculated Rx selling price.
In pharmacy procurement, terms, availability and process cost should be assessed together. A low list price loses value when partial deliveries, shortages, repeat orders and manual searches consume the gain. Supplier scorecards should combine price, availability, returns, service, payment terms and internal workload.
Pharmaceutical wholesale: connect service levels to margin
Pharmaceutical wholesalers need to reconcile supply reliability, regulated price components and rising process costs. The key is a granular contribution model by customer, route, temperature band, order profile and service level.
Small orders, late cut-offs, emergency supply, high return rates and repeated delivery attempts may be necessary, but they need transparent measurement and a clear place in capacity and contract decisions.
Logistics: review contracts and SLAs against real drivers
For temperature-controlled pharmaceutical logistics, a general diesel surcharge is not enough. Relevant drivers include energy source, temperature band, shipment profile, distance, utilisation, waiting time, data requirements and exception handling.
Service-level agreements should define included services, surcharge formulas and evidence. Rules for temperature deviations, delays, returns, quarantine and quality decisions are equally important. This connects cost transparency with GDP responsibility.
Seven actions for the second half of 2026
- Update the cost base: use actual consumption and contract values.
- Segment cost-to-serve: separate customers, routes, temperature bands and special services.
- Review index clauses: define the reference, base period, thresholds and evidence.
- Optimise routes and cut-offs: raise utilisation and reduce avoidable second runs.
- Connect cooling and energy data: analyse consumption, stability and maintenance together.
- Diversify supplier risk: qualify alternatives for critical packaging, technology and consumables.
- Build a dashboard: combine indices with internal margin, availability, return and deviation KPIs.
Interpretation: what the statistics do not show
The index cannot show how much a specific medicine, transport lane or contract will cost. It measures average wholesale developments and cannot replace individual terms, quantities, durations or product mixes. It also does not establish a causal link between price changes and medicine shortages.
The right use is analytical, not automatic: the index identifies areas to review. Internal procurement, energy, route, warehouse and quality data determine whether action is required.
tiger.PHARMA: turning indices into operating decisions
tiger.PHARMA connects market and procurement data with pharmacy economics, wholesale processes and GDP-compliant logistics. We structure cost-to-serve, supplier and terms analyses, inventory steering and practical KPI models. Explore pharma data and smart sourcing, consulting for pharmaceutical wholesalers and pharmaceutical logistics and warehousing.